We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+13.4%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$10.9B
AUM Growth
+$1.67B
(+18%)
Cap. Flow
+$806M
Cap. Flow
% of AUM
7.42%
Top 10 Holdings %
Top 10 Hldgs %
14.27%
Holding
678
New
211
Increased
171
Reduced
126
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ERF
Enerplus Corporation
ERF
|
+$91.2M |
| 2 |
TE Connectivity
TEL
|
+$81.6M |
| 3 |
Palo Alto Networks
PANW
|
+$78.9M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$75.6M |
| 5 |
Honeywell
HON
|
+$70.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$113M |
| 2 |
AbbVie
ABBV
|
+$110M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
+$88.1M |
| 4 |
SPLK
Splunk Inc
SPLK
|
+$70.1M |
| 5 |
Synopsys
SNPS
|
+$64.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.5% |
| 2 | Technology | 22.75% |
| 3 | Industrials | 9.82% |
| 4 | Energy | 8.34% |
| 5 | Consumer Discretionary | 7.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LYRA
376
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $4.21M | 0.04% |
13,531
+1,531
| +13% | +$408K |
|
377
Amneal Pharmaceuticals
AMRX
$5.77B
| $4.17M | 0.04% |
+688,106
| New | +$3.88M |
|
378
Cabaletta Bio
CABA
$450M
| $4.14M | 0.04% |
242,663
+1,210
| +0.5% | +$26K |
|
379
ARS Pharmaceuticals
SPRY
$551M
| $4.11M | 0.04% |
401,788
-259,626
| -39% | -$1.94M |
|
380
Intel
INTC
$503B
| $4.06M | 0.04% |
+91,892
| New | +$4.09M |
|
381
Geron
GERN
$1.01B
| $4.01M | 0.04% |
+1,214,570
| New | +$2.72M |
|
|
RVPH
382
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $3.99M | 0.04% |
52,750
+46,730
| +776% | +$3.7M |
|
383
10x Genomics
TXG
$5.79B
| $3.95M | 0.04% |
+105,261
| New | +$4.62M |
|
384
Brighthouse Financial
BHF
$3.57B
| $3.93M | 0.04% |
+76,256
| New | +$3.79M |
|
385
New Oriental
EDU
$9.04B
| $3.87M | 0.04% |
+44,574
| New | +$3.78M |
|
386
Xponential Fitness
XPOF
$266M
| $3.87M | 0.04% |
233,731
-188,470
| -45% | -$2.32M |
|
|
EHAB
387
DELISTED
Enhabit
EHAB
| $3.85M | 0.04% |
+330,605
| New | +$3.31M |
|
388
Spyre Therapeutics
SYRE
$9.12B
| $3.81M | 0.04% |
+100,527
| New | +$2.91M |
|
389
Synaptics
SYNA
$3.99B
| $3.74M | 0.03% |
+38,367
| New | +$4.03M |
|
390
Trip.com Group
TCOM
$29.1B
| $3.7M | 0.03% |
+84,276
| New | +$3.42M |
|
|
TRML
391
DELISTED
Tourmaline Bio
TRML
| $3.6M | 0.03% |
+157,359
| New | +$5.55M |
|
|
MORF
392
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.52M | 0.03% |
+100,000
| New | +$3.35M |
|
393
HCA Healthcare
HCA
$88.5B
| $3.49M | 0.03% |
10,469
-56,321
| -84% | -$17.2M |
|
394
Lumentum
LITE
$65.2B
| $3.48M | 0.03% |
73,584
-68,182
| -48% | -$3.47M |
|
395
Domo
DOMO
$179M
| $3.45M | 0.03% |
386,818
+53,696
| +16% | +$558K |
|
396
SAP
SAP
$230B
| $3.36M | 0.03% |
17,207
+15,504
| +910% | +$2.75M |
|
|
ATYR
397
aTyr Pharma
ATYR
$49.2M
| $3.28M | 0.03% |
+1,681,279
| New | +$2.93M |
|
|
AKRO
398
DELISTED
Akero Therapeutics
AKRO
| $3.24M | 0.03% |
+128,441
| New | +$3.08M |
|
399
Unity
U
$17.8B
| $3.21M | 0.03% |
120,240
-316,405
| -72% | -$9.94M |
|
400
Booz Allen Hamilton
BAH
$8.89B
| $3.14M | 0.03% |
+21,147
| New | +$2.98M |
|
Similar funds
TCIIS
UIM
VAI
KK
Woodline Partners's Q1 2024 Portfolio in Review
As of Q1 2024, Woodline Partners held 678 positions worth $10.9B, up 18% from $9.2B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Woodline Partners deployed $806M of net new capital in Q1 2024, opening 211 new positions and adding to 171 existing holdings. Its largest new stake was Enerplus Corporation: 5,602,613 shares worth $110M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 41% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was AbbVie, an estimated $110M trimmed.
- Woodline Partners's largest Q1 2024 buy was Enerplus Corporation: 5,602,613 shares worth $110M.
- Woodline Partners added most to TE Connectivity in Q1 2024, an estimated $81.6M increase.
- Woodline Partners's biggest Q1 2024 reduction was AbbVie, cutting an estimated $110M.
- Woodline Partners fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $113M.
- Woodline Partners's ten largest holdings make up 14% of its $10.9B portfolio in Q1 2024.
- Woodline Partners opened 211 new positions and closed 150 in Q1 2024.
- Woodline Partners's portfolio value rose 18% quarter-over-quarter to $10.9B.
Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.